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ABSTRACT
Phosphaturic mesenchymal tumors (PMTs) are very rare tumors which are frequently associated with Tumor Induced 
Osteomalacia (TIO), a paraneoplastic syndrome that manifests as renal phosphate wasting. The tumor cells produce a 
peptide hormone-like substance known as fibroblast growth factor 23 (FGF23), a physiologic regulator of phosphate 
levels. FGF23 decreases proximal tubule reabsorption of phosphates and inhibits 1-α-hydroxylase, which reduces levels 
of 1-α, 25-dihydroxyvitamine D3. Thus, overexpression of FGF23 by the tumor cells leads to increased excretion of 
phosphate in the urine, mobilization of calcium and phosphate from bones, and the reduction of osteoblastic activity, 
ultimately resulting in widespread osteomalacia. Patients typically present with gradual muscular weakness and diffuse 
bone pain from pathologic fractures. The diagnosis is often delayed due to the non-specific nature of the symptoms and 
lack of clinical suspicion. While serum phosphorus and FGF23 testing can assist in making a clinical diagnosis of PMT, 
the responsible tumor is often difficult to locate. The pathologic diagnosis is often missed due to the rarity of PMTs and 
histologic overlap with other mesenchymal neoplasms. While patients can experience severe disabilities without treatment, 
excision is typically curative and results in a dramatic reversal of symptoms. Histologically, PMT has a variable appearance 
and can resemble other low grade mesenchymal tumors. Even though very few cases of PMT have been reported in 
the world literature, it is very important to consider this diagnosis in all patients with hypophosphatemic osteomalacia. 
Here we present a patient who suffered for almost 5 years without a diagnosis. Ultimately, the PMT was located on a 
68Ga-DOTA TATE PET/CT scan and subsequently confirmed by histologic and immunohistologic study. Interestingly, 
strong positivity for FGFR1 by IHC might be related to the recently described FN1-FGFR1 fusion. Upon surgical removal, 
the patient’s phosphate and FGF23 levels returned to normal and the patient’s symptoms resolved. 
Keywords 
Neoplasm, Connective Tissue; Oncogenic Osteomalacia; Fibroblast Growth factors; Hypophosphatemia; Bone Diseases, 
Metabolic.
INTRODUCTION
Phosphaturic mesenchymal tumors (PMTs) are very 
rare tumors which are frequently associated with Tumor 
Induced Osteomalacia (TIO), a paraneoplastic syndrome 
that manifests as renal phosphate wasting. The tumor 
cells produce a peptide hormone-like substance known 
as fibroblast growth factor 23 (FGF23), a physiologic 
regulator of phosphate levels.1 FGF23 decreases 
proximal tubule reabsorption of phosphates and 
Ghorbani-Aghbolaghi A, Darrow MA, Wang T
33Autops Case Rep (São Paulo). 2017;7(3):32-37
inhibits 1-α-hydroxylase, which reduces levels of 1-α, 
25-dihydroxy vitamin D3. Thus, overexpression of 
FGF23 by the tumor cells leads to increased clearance 
of phosphate in the urine, mobilization of calcium 
and phosphate from bones, and the reduction of 
osteoblastic activity, ultimately resulting in widespread 
osteomalacia.2
CASE REPORT
A 48-year-old man presented with a history of 
long-standing progressive low back pain, which has 
extended to the large joints, resulting in difficulty 
moving. A rheumatologic workup was negative and he 
was treated symptomatically with NSAIDs, glucosamine, 
and hydrocodone. He also had a pruritic rash on 
his lower legs. He was also seen by his primary care 
provider, dermatology, endocrinology, and hematology 
specialists. Additional workups revealed no evidence of 
hyperparathyroidism, myeloma, stiff person syndrome, 
mixed connective tissue disease, and Paget disease.
A CT scan revealed diffuse osteopenia with 
insufficiency fractures. His serum alkaline phosphate 
level was elevated while serum phosphate was 
decreased. Testing for FGF23 showed an increased 
serum level (240 RU/ml), which has a differential 
of X-linked hypophosphatemia (XLH), autosomal 
dominant hypophosphatemic rickets (ADHR), or PMT. 
His lack of family history argued against XLH and 
ADHR. Given the high clinical suspicion for a PMT, a 
PET scan was performed in an attempt to locate the 
PMT. This showed markedly PET avid right axillary 
adenopathy as well as a right hand mass. Biopsies of 
both sites were inconclusive for PMT. A repeat PET 
scan six months later did not show any new masses. 
A 68Ga-DOTA TATE PET/CT was performed and 
showed prominent uptake in an enlarged right inguinal 
lymph node, which was subsequently excised.
SURGICAL PATHOLOGY
The right inguinal mass specimen was received 
as a 3.0 x 3.0 x 0.8 cm piece of pink-tan tissue. 
Microscopically, the tumor consisted predominantly 
of bland spindle to stellate cells with a well-developed 
capillary network, foci of hemorrhage, hemosiderin 
deposition, and osteoclast-like multinucleate giant cells. 
Scattered calcifying matrix with “grungy” material was 
also identified (Figure 1A to 1D). A chromogenic in situ 
hybridization (CISH) study showed very strong positivity 
for FGF23 mRNA. FGFR1 immunohistochemistry 
was diffusely positive, implying the presence of the 
FN1-FGFR1 fusion (Figure 2A and 2B).
Laboratory test: One month after the right 
inguinal mass excision, the patient’s serum levels 
returned to normal and the patient’s symptoms 
decreased dramatically (Table 1)
DISCUSSION
Phosphate plays an important role in many cell 
functions, including oxygen delivery, energy generation, 
and DNA synthesis. Acute hypophosphatemia can 
lead to generalized weakness, malaise, hypotension, 
congestive heart failure, rhabdomyolysis, respiratory 
failure, seizures, and altered mental status. Because 
these symptoms are non-specific, hypophosphatemia 
may not init ial ly be suspected or recognized. 
Chronic hypophosphatemia results in defective bone 
mineralization, ultimately leading to osteomalacia 
in adults and rickets in children. The symptoms of 
osteomalacia and rickets include weakness, fractures, 
bone pain, and bowing of long bones.
Three pathogenic mechanisms are known to cause 
hypophosphatemia:3
1 - Inadequate phosphate intake (e.g. malnutrition, 
malabsorption, vitamin D deficiency, and use of 
phosphate binding antacids)
2 - Phosphate shifting from extracellular to intracellular 
spaces (e.g. acute respiratory alkalosis, refeeding 
syndrome, hungry bone syndrome, and treatment 
of diabetic ketoacidosis with insulin)
3 - Increase urine excretion (e.g. hyperparathyroidism, 
vitamin D deficiency, Fanconi syndrome, 
medications (diuretics, bisphosphonates), and 
tumors)
Tumor-induced osteomalacia (TIO) is a condition 
caused by the increased excretion of phosphate due 
to a tumor-secreted phosphaturic factor (so called 
“phosphatonins”).4 It can be seen in patients with 
phosphaturic mesenchymal tumor as well as some other 
mesenchymal tumors (such as hemangiopericytoma).5
Phosphaturic mesenchymal tumors (PMTs) are rare 
tumors that occurs most frequently in middle aged 
adults and can involve essentially any bone or soft 
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Figure 1. Photomicrography of the tumor with A – Hypercellular and hypocellular areas, hemorrhage and vascular 
network; B – Bland spindled cells and unusual basophilic matrix a “grungy” calcification pattern; C – Cellular proliferation 
of bland spindle cells with scattered osteoblasts and hemosiderin; D – The neoplastic cells produce smudgy calcifications.
Figure 2 . Photomicrography of the tumor showing in A – Tumor cells are strongly positive for FGF23 mRNA by 
CISH; B – Strong positivity for FGFR1 by IHC, implying the presence of the FN1-FGFR1 fusion.
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tissue location.6 It typically causes osteomalacia through 
secreting circulating FGF23, which leads to renal 
wasting of phosphate and consequently causes tumor 
induced osteomalacia. Clinical features comprise bone 
pain, generalized weakness, and pathologic fractures.1 
Histologically, PMTs are characterized by a proliferation 
of bland spindle cells associated with a variable amount 
of ‘smudgy’ calcified matrix. A small subset of PMTs 
exhibit malignant histologic features and may behave 
in a clinically malignant fashion.7 Because PMTs are 
rare, the diagnosis is often not considered by clinicians 
and pathologists, even in patients presenting with 
osteomalacia. Thus, most patients ultimately diagnosed 
with PMT have experienced osteomalacia for years 
before the tumor is identified.8 Measurement of serum 
FGF23 can assist in diagnosis and management of 
disorders of phosphate and bone metabolism. A high 
FGF23 level in a patient with normal renal function, 
hypophosphatemia, and with or without osteomalacia, 
is suggestive of PMT. FGF23 is located on chromosome 
12 and is composed of three exons. Mutations in 
FGF23 that render the protein resistant to proteolytic 
cleavage lead to increased activity of FGF23 and renal 
phosphate loss. It was first discovered in 2000 in the 
autosomal dominant hypophosphatemic rickets.9 
The best-established receptor of FGF23 is FGFR1, 
which on ligand binding and activation conducts 
its signaling pathways to regulate cell proliferation, 
survival, migration, and differentiation.10
In 2015, a novel FN1-FGFR1 fusion protein was 
identified in nine out of fifteen PMTs by Jen-Chieh 
Lee et al., using RT-PCR in addition to FISH and Western 
blot analysis. One year later, they systematically 
characterized the prevalence of the FN1–FGFR1 and 
another novel FN1–FGF1 fusion in a larger group of 
well-characterized phosphaturic mesenchymal tumors, 
suggesting the central role of FGFR1 signaling in the 
pathogenesis of phosphaturic mesenchymal tumors. 
As in the FN1–FGFR1 fusion gene, the FN1 gene 
likely provides its transcriptionally active promoter 
to drive the expression of FN1–FGF1 protein.11 FN1 
(Fibronectin 1), a protein-coding gene on chromosome 
2, plays a major role in cell adhesion, growth, 
migration, and differentiation.12 Altered fibronectin 
expression, degradation, and organization have been 
associated with a number of disorders, including cancer 
and fibrosis.13,14 Because both fibronectin and FGF1 
are secretory proteins, the FN1–FGF1 fusion protein 
is expected to be secreted in the form of a fusion 
protein which contains nearly the entirety of FGF1, 
and when secreted at high levels, could presumably 
function like normal FGF1 in excess. FGF1 protein is a 
crucial ligand for all FGFRs.15 It acts as a potent mitogen 
of fibroblasts and is involved in critical biological 
functions including development, morphogenesis, 
and angiogenesis.16 FN1–FGFR1 proteins could use the 
self-assembly and fibronectin-binding domains of the 
FN1 part to dimerize, perhaps with the assistance of 
extracellular matrix. The FGFs secreted by the tumor 
cells could bind the ligand-binding domains of the 
FGFR1 part to facilitate the dimerization and activation 
of the fusion protein, which would likely dimerize 
and bind the membranous FGFR1 in a 2:2 ternary 
fashion. Both pathways will converge in the activation 
of FGFR1 signaling, which upregulates the expression 
of FGF23.17 α-Klotho is an obligatory co-receptor 
for FGF23–FGFR1 binding, and its expression is 
mostly limited to renal tubules, choroid plexus, 
and parathyroid gland under normal physiologic 
condition.18 FGF23 binds to the FGFR-klotho complex 
on the apical surface of the proximal renal tubule, 
which results in decreased phosphate reabsorption 
and consequent hypophosphatemia.19
Table 1. Laboratory results pre- and post tumoral excision
Lab results
Calcium
mg/dL
PO4
mg/dL
24 hr Urine 
PO4
mg/d
PTH
pg/mL
FGF23
RU/mL
ALP
U/L
Reference range 8.4-10.5 2.4-5.0 400-1300 12-88 <=180 35-115
Before surgery 8.4 1.6 (L) 1819 (H) 207 (H) 240 (H) 462 (H)
1 month post-surgery 9.5 4.0 426 30 98 125 (H)
ALP = alkaline phosphatase; FGF23 = Fibroblast growth factor 23; PO4 = phosphate; PTH = paratohormone.
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The main function of FGF23 seems to be 
regulation of phosphate concentration in plasma. 
FGF23 is secreted by osteocytes in response to 
elevated calcitriol. It inhibits renal Pi reabsorption by 
reducing the apical expression and activity of NaPi-IIa 
in the proximal tubule epithelium.20 FGF23 also 
reduces intestinal absorption of dietary Pi through 
a vitamin D receptor (VDR)-dependent decrease in 
NaPi-IIb activity. The latter phenomenon is most likely 
secondary to FGF23-mediated reduction of circulating 
1,25(OH)2 D3 synthesis through suppression of 
D-1alpha-hydroxylase expression in the kidney.21 
Multiple FGF Receptors (FGFRs) can act as receptors 
for FGF23 when bound by the co-receptor Klotho 
expressed in the renal tubular epithelium.9 FGFRs 
also regulate skeletal FGF23 secretion; ectopic FGFR 
activation is implicated in genetic conditions associated 
with FGF23 overproduction and hypophosphatemia.22
CONCLUSION
Phosphaturic mesenchymal tumor (PMT) is a rare 
distinctive mesenchymal neoplasm with heterogeneous 
but recognizable histologic appearances. It frequently 
elicits a clinical paraneoplastic syndrome consisting of 
hypophosphatemic hyperphosphaturic osteomalacia 
due to increased secretion of FGF23. The patients 
typically present with gradual muscular weakness, 
bone pain, and pathologic fractures. The diagnosis is 
commonly delayed for years due to the non-specific 
nature of these symptoms, lack of clinical suspicion, 
failure to include serum phosphorus levels in routine 
blood chemistry testing, and difficulty in identifying 
the responsible tumor. Additionally, these tumors 
are often missed histologically because of their rarity 
and morphologic overlap with other mesenchymal 
neoplasms. Complete excision of the tumor is crucial as 
it typically result in the resolution of the osteomalacia, 
clinical symptoms, and laboratory abnormalities.
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